The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
- 5 March 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Infection
- Vol. 65 (1), 17-24
- https://doi.org/10.1016/j.jinf.2012.02.017
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort studyThe Lancet Infectious Diseases, 2011
- The Potential Role for Protein-Conjugate Pneumococcal Vaccine in Adults: What Is the Supporting Evidence?Clinical Infectious Diseases, 2011
- Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006Journal of Infection, 2010
- Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluationVaccine, 2010
- A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected AdultsThe New England Journal of Medicine, 2010
- Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort StudyPLoS Medicine, 2009
- Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategiesBMC Infectious Diseases, 2008
- Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999–2005Epidemiology and Infection, 2007
- Pneumococcal Polysaccharide Vaccine EfficacyJAMA, 1993
- The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide VaccineThe New England Journal of Medicine, 1991